EU green light for Zogenix’s Fintepla
Oral solution approved to treat seizures associated with Dravet syndrome
Read More
Tag: zogenix
Zogenix submits new drug application to FDA for Fintepla
Zogenix has completed its rolling submission of a New Drug Application in the US and submitted a marketing application in Europe for Fintepla for the treatment of seizures associated with Dravet syndrome.
Read More
Zogenix’ drug cuts seizures in Dravet syndrome
Zogenix has revealed top-line results from a second late-stage trial of its investigational Dravet syndrome drug ZX008, showing a significant reduction in seizures.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
